AU2007267860B2 - Triazole compounds that modulate Hsp90 activity - Google Patents

Triazole compounds that modulate Hsp90 activity Download PDF

Info

Publication number
AU2007267860B2
AU2007267860B2 AU2007267860A AU2007267860A AU2007267860B2 AU 2007267860 B2 AU2007267860 B2 AU 2007267860B2 AU 2007267860 A AU2007267860 A AU 2007267860A AU 2007267860 A AU2007267860 A AU 2007267860A AU 2007267860 B2 AU2007267860 B2 AU 2007267860B2
Authority
AU
Australia
Prior art keywords
optionally substituted
diol
hydroxy
triazol
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007267860A
Other languages
English (en)
Other versions
AU2007267860A1 (en
Inventor
Dinesh U. Chimmanamada
Zhenjian Du
Kevin Foley
Teresa Przewloka
Shuzhen Qin
Weiwen Ying
Shijie Zhang
Dan Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of AU2007267860A1 publication Critical patent/AU2007267860A1/en
Application granted granted Critical
Publication of AU2007267860B2 publication Critical patent/AU2007267860B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2007267860A 2006-05-25 2007-05-25 Triazole compounds that modulate Hsp90 activity Ceased AU2007267860B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80825106P 2006-05-25 2006-05-25
US60/808,251 2006-05-25
PCT/US2007/012544 WO2007139968A2 (en) 2006-05-25 2007-05-25 Triazole compounds that modulate hsp90 activity

Publications (2)

Publication Number Publication Date
AU2007267860A1 AU2007267860A1 (en) 2007-12-06
AU2007267860B2 true AU2007267860B2 (en) 2012-08-09

Family

ID=38656659

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007267860A Ceased AU2007267860B2 (en) 2006-05-25 2007-05-25 Triazole compounds that modulate Hsp90 activity

Country Status (7)

Country Link
US (3) US8183384B2 (enExample)
EP (1) EP2038262B1 (enExample)
JP (1) JP5410965B2 (enExample)
AU (1) AU2007267860B2 (enExample)
CA (1) CA2653332A1 (enExample)
TW (1) TWI490212B (enExample)
WO (1) WO2007139968A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1817295E (pt) 2004-11-18 2013-02-18 Synta Pharmaceuticals Corp Compostos de triazol que modulam a actividade da hsp90
CA2618377A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
CA2618628C (en) 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
PL2035396T3 (pl) 2006-05-25 2014-10-31 Synta Pharmaceuticals Corp Związki triazolowe modulujące aktywność hsp90
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
JP5441690B2 (ja) 2006-05-25 2014-03-12 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
CA2653327A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
US8063083B2 (en) 2006-05-25 2011-11-22 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
MX2009008547A (es) * 2007-02-08 2010-01-15 Synta Pharmaceuticals Corp Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer.
AU2008287367B2 (en) * 2007-08-13 2012-02-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
WO2009075890A2 (en) * 2007-12-12 2009-06-18 Synta Pharmaceuticals Corp. Method for synthesis of triazole compounds that modulate hsp90 activity
US9156836B2 (en) * 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
BRPI0909985A2 (pt) * 2008-06-03 2015-08-25 Siga Technologies Inc Composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada à mesma
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
US8648071B2 (en) 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
WO2010017479A1 (en) * 2008-08-08 2010-02-11 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011085269A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Raf kinase inhibitors
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2012155063A1 (en) * 2011-05-11 2012-11-15 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
CA2840986A1 (en) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
US20140286902A1 (en) 2011-11-02 2014-09-25 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
CN102796052B (zh) * 2012-09-06 2014-08-13 河南师范大学 具有抗真菌活性的丹皮酚-1,2,3-三氮唑类化合物及其制备方法
CN104072395B (zh) * 2013-03-25 2016-08-24 黄蓬 一种异硫氰酸酯及其制备方法与抗癌应用
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
AU2014318826B2 (en) 2013-09-10 2019-10-10 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2015066053A2 (en) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
AU2015224576A1 (en) 2014-03-03 2016-09-22 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
GB201410214D0 (en) 2014-06-09 2014-07-23 Univ Surrey A method for graphene and carbon nanotube growth
CN113105403A (zh) * 2016-05-03 2021-07-13 拜耳制药股份公司 制备5-羟基烷基-取代的1-苯基-1,2,4-三唑衍生物的方法
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN111328327A (zh) 2017-08-31 2020-06-23 北兴化学工业株式会社 1-(n,n-二取代的氨基甲酰基)4-(取代的磺酰基)三唑啉-5-酮衍生物、4-(n,n-二取代的氨基甲酰基)1-(取代的磺酰基)三唑啉-5-酮衍生物和包含这些衍生物作为有效成分的除草剂
EP3653611A1 (en) * 2018-11-15 2020-05-20 Centre National De La Recherche Scientifique Inhibitors of metallo-beta-lactamases
WO2020227368A1 (en) * 2019-05-08 2020-11-12 Trustees Of Boston University Hsp90 inhibitors and uses thereof
CN116134025B (zh) * 2020-09-17 2025-04-04 浙江海正药业股份有限公司 酰胺膦氧类衍生物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869509A (en) * 1996-07-31 1999-02-09 Bristol-Myers Squibb Company Diphenyl oxadiazolones as potassium channel modulators
WO2005087750A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
WO2005097758A1 (en) * 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB928919A (en) 1960-08-16 1963-06-19 Bellon Labor Sa Roger Triazole derivatives and a process for their preparation
US4269846A (en) 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
JPS5910574A (ja) 1982-07-07 1984-01-20 Fujisawa Pharmaceut Co Ltd トリアゾ−ル誘導体およびその製造法
FR2546887B1 (fr) 1983-05-30 1985-08-30 Paris 7 Universite Procede de preparation de dihydro-2,4 triazol-1,2,4 thiones-3 disubstituees en positions 4 et 5 et nouveaux composes pouvant etre prepares par ce procede
US4624995A (en) 1985-04-09 1986-11-25 Minnesota Mining And Manufacturing Company Triazolinethione-containing polymer
US4740568A (en) 1985-04-09 1988-04-26 Minnesota Mining And Manufacturing Company Triazolinethione-containing polymer
US5436252A (en) 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US5006650A (en) 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
DE3729070A1 (de) 1987-09-01 1989-03-09 Bayer Ag Substituierte triazolinone
SK278998B6 (sk) 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
DE69330713T2 (de) 1992-03-13 2002-07-04 Merck Sharp & Dohme Ltd., Hoddesdon Imidazol-, triazol- und tetrazolderivate
FR2690277A1 (fr) * 1992-04-15 1993-10-22 Picogica Sa Circuit intégré à transistors complémentaires à effet de champ à hétérojonction.
TW218017B (enExample) 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd
DE4222771A1 (de) 1992-07-10 1994-01-13 Bayer Ag Heterocyclyltriazolinone
DE4303376A1 (de) 1993-02-05 1994-08-11 Bayer Ag Substituierte Triazolinone
DE4303676A1 (de) 1993-02-09 1994-08-11 Bayer Ag 1-Aryltriazolin(thi)one
US5538988A (en) 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
US5489598A (en) 1994-06-08 1996-02-06 Warner-Lambert Company Cytoprotection utilizing aryltriazol-3-thiones
JP3372365B2 (ja) 1994-08-19 2003-02-04 富士写真フイルム株式会社 ハロゲン化銀写真感光材料およびそれを用いた画像形成方法
DE19521162A1 (de) 1995-06-09 1996-12-12 Bayer Ag N-Aryl-1,2,4-triazolin-5-one
EP0938487A2 (en) 1996-11-12 1999-09-01 Sepracor, Inc. 2$i(R),4$i(S),$i(R),$i(S)- AND 2$i(S),4$i(R),$i(R),$i(S)-HYDROXYITRACONAZOLE- AND HYDROXYSAPERCONAZOLE DERIVATIVES
JP3788676B2 (ja) 1997-11-11 2006-06-21 富士写真フイルム株式会社 有機エレクトロルミネツセンス素子材料およびそれを使用した有機エレクトロルミネツセンス素子
AU3254099A (en) 1998-03-09 1999-09-27 Basf Aktiengesellschaft Hetaryl-substituted benzyl phenyl ethers, method for the production thereof, andtheir use for combating harmful fungi and animal pests
JP2000284412A (ja) 1999-03-30 2000-10-13 Fuji Photo Film Co Ltd 熱現像写真材料
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
JP4102124B2 (ja) 2001-08-01 2008-06-18 富士フイルム株式会社 ハロゲン化銀乳剤およびハロゲン化銀写真感光材料
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
JP2005084612A (ja) 2003-09-11 2005-03-31 Fuji Photo Film Co Ltd ハロゲン化銀乳剤、ハロゲン化銀感光材料、および熱現像感光材料
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2005044194A2 (en) * 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
PT1817295E (pt) * 2004-11-18 2013-02-18 Synta Pharmaceuticals Corp Compostos de triazol que modulam a actividade da hsp90
WO2006095783A1 (ja) * 2005-03-09 2006-09-14 Nippon Kayaku Kabushiki Kaisha 新規なｈｓｐ９０阻害剤
US8399464B2 (en) * 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
CA2618628C (en) * 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869509A (en) * 1996-07-31 1999-02-09 Bristol-Myers Squibb Company Diphenyl oxadiazolones as potassium channel modulators
WO2005087750A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
WO2005097758A1 (en) * 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof

Also Published As

Publication number Publication date
TWI490212B (zh) 2015-07-01
US8329736B2 (en) 2012-12-11
US20080004277A1 (en) 2008-01-03
CA2653332A1 (en) 2007-12-06
US20120202813A1 (en) 2012-08-09
US8183384B2 (en) 2012-05-22
AU2007267860A1 (en) 2007-12-06
EP2038262A2 (en) 2009-03-25
US20130072461A1 (en) 2013-03-21
EP2038262B1 (en) 2014-11-12
WO2007139968A3 (en) 2008-10-02
JP2009538322A (ja) 2009-11-05
TW200808746A (en) 2008-02-16
WO2007139968A2 (en) 2007-12-06
JP5410965B2 (ja) 2014-02-05

Similar Documents

Publication Publication Date Title
AU2007267860B2 (en) Triazole compounds that modulate Hsp90 activity
AU2008287367B2 (en) Triazole compounds that modulate HSP90 activity
AU2008232354B9 (en) Triazinone and diazinone derivatives useful as Hsp90 inhibitors
CA2677481C (en) Triazole compounds that modulate hsp90 activity
US9006277B2 (en) Triazole compounds that modulate HSP90 activity
AU2007267847B2 (en) Triazole compounds that modulate Hsp90 activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired